Trial 0S-17-6


PhII-155 A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Biological Response Modifier
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Lusine Raddatz, D.M., Victoria Amran, D.M., Grace Facio, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Marile Garcia, Coordinator, Gina Tse, Coordinator, Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Bartolo Santos, Coordinator, Peter Alexander, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.